Last reviewed · How we verify
H-VA dual therapy
H-VA dual therapy combines hepatitis B virus (HBV) and hepatitis A virus (HAV) immunization in a single formulation to provide dual protection against both viral infections.
H-VA dual therapy combines hepatitis B virus (HBV) and hepatitis A virus (HAV) immunization in a single formulation to provide dual protection against both viral infections. Used for Prevention of hepatitis A and hepatitis B virus infections in susceptible populations.
At a glance
| Generic name | H-VA dual therapy |
|---|---|
| Also known as | H-VA |
| Sponsor | The First Affiliated Hospital of Nanchang University |
| Drug class | Combination vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is a combination vaccine that stimulates immune responses against both hepatitis A and hepatitis B antigens simultaneously. By targeting two distinct hepatotropic viruses in one therapeutic regimen, it aims to improve patient compliance and provide comprehensive protection against both HAV and HBV infections.
Approved indications
- Prevention of hepatitis A and hepatitis B virus infections in susceptible populations
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Fatigue
- Myalgia
Key clinical trials
- VA Dual Sequential Therapy (PHASE4)
- Helicobacter Pylori and Vonoprazan Dual Therapy (PHASE4)
- Optimization of Vonoprazan--amoxicillin Dual Therapy for Eradicating Helicobacter Pyloriinfection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H-VA dual therapy CI brief — competitive landscape report
- H-VA dual therapy updates RSS · CI watch RSS
- The First Affiliated Hospital of Nanchang University portfolio CI